Blamey RW - Search Results

1

Cellular effects of tamoxifen in primary breast cancer.

Robertson JF, Ellis IO, Nicholson RI, Robins A, Bell J, Blamey RW. Robertson JF, et al. Among authors: blamey rw. Breast Cancer Res Treat. 1992 Jan;20(2):117-23. doi: 10.1007/BF01834641. Breast Cancer Res Treat. 1992. PMID: 1554887

2

P-glycoprotein expression in locally advanced breast cancer treated by neoadjuvant chemotherapy.

Dixon AR, Bell J, Ellis IO, Elston CW, Blamey RW. Dixon AR, et al. Among authors: blamey rw. Br J Cancer. 1992 Sep;66(3):537-41. doi: 10.1038/bjc.1992.309. Br J Cancer. 1992. PMID: 1355661 Free PMC article.

3

p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.

Poller DN, Hutchings CE, Galea M, Bell JA, Nicholson RA, Elston CW, Blamey RW, Ellis IO. Poller DN, et al. Among authors: blamey rw. Br J Cancer. 1992 Sep;66(3):583-8. doi: 10.1038/bjc.1992.318. Br J Cancer. 1992. PMID: 1355662 Free PMC article.

4

The Nottingham Prognostic Index in primary breast cancer.

Galea MH, Blamey RW, Elston CE, Ellis IO. Galea MH, et al. Among authors: blamey rw. Breast Cancer Res Treat. 1992;22(3):207-19. doi: 10.1007/BF01840834. Breast Cancer Res Treat. 1992. PMID: 1391987

5

Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy.

Robertson JF, Dixon AR, Nicholson RI, Ellis IO, Elston CW, Blamey RW. Robertson JF, et al. Among authors: blamey rw. Breast Cancer Res Treat. 1992;22(3):221-7. doi: 10.1007/BF01840835. Breast Cancer Res Treat. 1992. PMID: 1391988

6

Tumour oestrogen receptor content allows selection of elderly patients with breast cancer for conservative tamoxifen treatment.

Low SC, Dixon AR, Bell J, Ellis IO, Elston CW, Robertson JF, Blamey RW. Low SC, et al. Among authors: blamey rw. Br J Surg. 1992 Dec;79(12):1314-6. doi: 10.1002/bjs.1800791224. Br J Surg. 1992. PMID: 1486427 Clinical Trial.

7

Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up.

Robertson JF, Ellis IO, Elston CW, Blamey RW. Robertson JF, et al. Among authors: blamey rw. Eur J Cancer. 1992;28A(4-5):908-10. doi: 10.1016/0959-8049(92)90148-u. Eur J Cancer. 1992. PMID: 1524922 Clinical Trial.

8

Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer.

Robertson JF, Bates K, Pearson D, Blamey RW, Nicholson RI. Robertson JF, et al. Among authors: blamey rw. Br J Cancer. 1992 May;65(5):727-30. doi: 10.1038/bjc.1992.153. Br J Cancer. 1992. PMID: 1534019 Free PMC article.

9

Heterogeneity of oestrogen receptor expression in normal and malignant breast tissue.

Walker KJ, McClelland RA, Candlish W, Blamey RW, Nicholson RI. Walker KJ, et al. Among authors: blamey rw. Eur J Cancer. 1992;28(1):34-7. doi: 10.1016/0959-8049(92)90379-g. Eur J Cancer. 1992. PMID: 1567686

10

Silver-stained nucleolar organiser region counts are of no prognostic value in primary breast cancer.

Sacks NP, Robertson JF, Ellis IO, Nicholson RI, Crocker J, Blamey RW. Sacks NP, et al. Among authors: blamey rw. Eur J Surg Oncol. 1992 Apr;18(2):98-102. Eur J Surg Oncol. 1992. PMID: 1582518

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

349 results

Search Page

Filters